Website selection

Health HCP Logo

Not a Healthcare Professional? visit our Public Site

GSK logo

Flixotide™

fluticasone propionate

Product Overview

What is Flixotide™:

Fluticasone propionate is a corticosteroid, administered by inhalation for the prophylactic treatment of asthma in adults and children.

Flixotide™ Inhaler Devices:

Fluticasone propionate is available in 3 different types of inhaler devices:

  • a cfc-free metered dose inhaler called the Evohaler™,
  • the breath-actuated Accuhaler™
  • and the Diskhaler™

Nebules™ are used with a nebuliser that converts the liquid inside the Nebules™ into particles that can be inhaled allowing delivery of a higher dose of fluticasone propionate than the other inhalers.

Formulations of Flixotide™:

  • Accuhaler™is a multi-dose dry powder inhalation device with 28 or 60 blisters each containing a mixture of microfine fluticasone propionate (50μg, 100μg, 250μg or 500μg).
  • Diskhaler™ contains a micronised powder for inhalation at 100,250μg or 500μg fluticasone propionate.
  • Evohaler™ is a pressurised inhaler containing suspensions, delivering either 50, 125 or 250μg of fluticasone propionate per actuation, respectively.
  • Nebules™ is an inhalation suspension for nebulisation containing 0.5mg fluticasone propionate or 2mg fluticasone propionate in 2ml of a buffered, isotonic saline suspension.

 

For further information on fluticasone propionate please download the relevant Flixotide™ Summary of Product Characteristics (SPC) [1] [2] [3] [4] [5] [6] [7]

 


References:

  1. Flixotide 50, 125, 250μg Evohaler™ Summary of Product Characteristics

  2. Flixotide Diskhaler™ 100μg Summary of Product Characteristics

  3. Flixotide Diskhaler™250μg Summary of Product Characteristics

  4. Flixotide Diskhaler™ 500μg Summary of Product Characteristics

  5. FlixotideAccuhaler™ Summary of Product Characteristics

  6. Flixotide Nebules™ 0.5mg/2ml Summary of Product Characteristics

  7. Flixotide Nebules™ 2mg/2ml Summary of Product Characteristics

I.E: Last updated 27 July 2010: UK/FP/0001/10